Merck Millipore Announces Co-marketing Agreement with groninger
News Aug 13, 2013
Merck Millipore has announced a co-marketing agreement with groninger, a leading provider of filling and packaging equipment for the pharmaceutical industry.
Moving forward, Merck Millipore will be groninger's partner of choice for single-use technology and groninger will be Merck Millipore's partner of choice for filling equipment.
Under the non-exclusive agreement, Merck Millipore will provide single-use filling products for use in conjunction with groninger's liquid filling equipment.
Merck Millipore's Mobius® single-use final fill assemblies offer greater flexibility than traditional options, allowing biopharmaceutical manufacturers to produce a variety of drug products and fill volumes with reduced process turnaround time and higher productivity.
By combining them with groninger's world-class liquid fill equipment, the co-marketing agreement will help customers accelerate the development and time-to-market of biopharmaceutical therapeutics.
Merck Millipore offers a full range of products, including Durapore® and Millipore Express® membranes for sterile filtration, the NovaSeptum® system for sterile sampling, the Lynx family® of sterile connectors and Provantage® Services for sterility training and qualification.
Taken together, Merck Millipore's sterility assurance solutions help biopharmaceutical manufacturers deliver a safe final product.
"The biopharmaceutical industry is facing increasingly complex drug production demands, as therapeutic drugs in development have smaller lot sizes and highly potent ingredients," said Vin Donovan, Vice President of Biopharm Process Solutions.
Donovan continued, "This new partnership will allow us to help our customers address these new challenges while ensuring the safety of their filling operations. This new agreement reflects our commitment to growing our relationships with top-tier partners to better enhance our industry solutions."
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Sequencing Shows How Evolution Can Undermine Bioprocess CommercializationNews
Rapid evolution can suppress the effect of pro-production genes in biochemical processes.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018